None provided


The following timeline graph is generated from all co-authored publications.

Featured publications are shown below:

  1. Interaction of three regiospecific amino acid residues is required for OATP1B1 gain of OATP1B3 substrate specificity. DeGorter MK, Ho RH, Leake BF, Tirona RG, Kim RB (2012) Mol Pharm 9(4): 986-95
    › Primary publication · 22352740 (PubMed) · PMC3319192 (PubMed Central)
  2. Striking In vivo phenotype of a disease-associated human SCN5A mutation producing minimal changes in vitro. Watanabe H, Yang T, Stroud DM, Lowe JS, Harris L, Atack TC, Wang DW, Hipkens SB, Leake B, Hall L, Kupershmidt S, Chopra N, Magnuson MA, Tanabe N, Knollmann BC, George AL, Roden DM (2011) Circulation 124(9): 1001-11
    › Primary publication · 21824921 (PubMed) · PMC3297976 (PubMed Central)
  3. Functional characterization of genetic variants in the apical sodium-dependent bile acid transporter (ASBT; SLC10A2). Ho RH, Leake BF, Urquhart BL, Gregor JC, Dawson PA, Kim RB (2011) J Gastroenterol Hepatol 26(12): 1740-8
    › Primary publication · 21649730 (PubMed) · PMC3170668 (PubMed Central)
  4. Informatic and functional approaches to identifying a regulatory region for the cardiac sodium channel. Atack TC, Stroud DM, Watanabe H, Yang T, Hall L, Hipkens SB, Lowe JS, Leake B, Magnuson MA, Yang P, Roden DM (2011) Circ Res 109(1): 38-46
    › Primary publication · 21566215 (PubMed) · PMC3135383 (PubMed Central)
  5. In vitro and in vivo assessment of renal drug transporters in the disposition of mesna and dimesna. Cutler MJ, Urquhart BL, Velenosi TJ, Meyer Zu Schwabedissen HE, Dresser GK, Leake BF, Tirona RG, Kim RB, Freeman DJ (2012) J Clin Pharmacol 52(4): 530-42
    › Primary publication · 21505084 (PubMed)
  6. Identification of novel functional organic anion-transporting polypeptide 1B3 polymorphisms and assessment of substrate specificity. Schwarz UI, Meyer zu Schwabedissen HE, Tirona RG, Suzuki A, Leake BF, Mokrab Y, Mizuguchi K, Ho RH, Kim RB (2011) Pharmacogenet Genomics 21(3): 103-14
    › Primary publication · 21278621 (PubMed) · PMC3044558 (PubMed Central)
  7. Modulation of drug block of the cardiac potassium channel KCNA5 by the drug transporters OCTN1 and MDR1. Yang T, McBride BF, Leake BF, Kim RB, Roden DM (2010) Br J Pharmacol 161(5): 1023-33
    › Primary publication · 20977453 (PubMed) · PMC2998684 (PubMed Central)
  8. Polymorphic variants in the human bile salt export pump (BSEP; ABCB11): functional characterization and interindividual variability. Ho RH, Leake BF, Kilkenny DM, Meyer Zu Schwabedissen HE, Glaeser H, Kroetz DL, Kim RB (2010) Pharmacogenet Genomics 20(1): 45-57
    › Primary publication · 20010382 (PubMed) · PMC2883163 (PubMed Central)
  9. Human skeletal muscle drug transporters determine local exposure and toxicity of statins. Knauer MJ, Urquhart BL, Meyer zu Schwabedissen HE, Schwarz UI, Lemke CJ, Leake BF, Kim RB, Tirona RG (2010) Circ Res 106(2): 297-306
    › Primary publication · 19940267 (PubMed)
  10. Breast cancer resistance protein (ABCG2) and drug disposition: intestinal expression, polymorphisms and sulfasalazine as an in vivo probe. Urquhart BL, Ware JA, Tirona RG, Ho RH, Leake BF, Schwarz UI, Zaher H, Palandra J, Gregor JC, Dresser GK, Kim RB (2008) Pharmacogenet Genomics 18(5): 439-48
    › Primary publication · 18408567 (PubMed) · PMC4043148 (PubMed Central)
  11. A common polymorphism in the bile acid receptor farnesoid X receptor is associated with decreased hepatic target gene expression. Marzolini C, Tirona RG, Gervasini G, Poonkuzhali B, Assem M, Lee W, Leake BF, Schuetz JD, Schuetz EG, Kim RB (2007) Mol Endocrinol 21(8): 1769-80
    › Primary publication · 17519356 (PubMed)
  12. Naringin is a major and selective clinical inhibitor of organic anion-transporting polypeptide 1A2 (OATP1A2) in grapefruit juice. Bailey DG, Dresser GK, Leake BF, Kim RB (2007) Clin Pharmacol Ther 81(4): 495-502
    › Primary publication · 17301733 (PubMed)
  13. Intestinal drug transporter expression and the impact of grapefruit juice in humans. Glaeser H, Bailey DG, Dresser GK, Gregor JC, Schwarz UI, McGrath JS, Jolicoeur E, Lee W, Leake BF, Tirona RG, Kim RB (2007) Clin Pharmacol Ther 81(3): 362-70
    › Primary publication · 17215845 (PubMed)
  14. Ritonavir, saquinavir, and efavirenz, but not nevirapine, inhibit bile acid transport in human and rat hepatocytes. McRae MP, Lowe CM, Tian X, Bourdet DL, Ho RH, Leake BF, Kim RB, Brouwer KL, Kashuba AD (2006) J Pharmacol Exp Ther 318(3): 1068-75
    › Primary publication · 16720753 (PubMed)
  15. Drug and bile acid transporters in rosuvastatin hepatic uptake: function, expression, and pharmacogenetics. Ho RH, Tirona RG, Leake BF, Glaeser H, Lee W, Lemke CJ, Wang Y, Kim RB (2006) Gastroenterology 130(6): 1793-806
    › Primary publication · 16697742 (PubMed)
  16. Development and characterization of LLC-PK1 cells containing Sprague-Dawley rat Abcb1a (Mdr1a): comparison of rat P-glycoprotein transport to human and mouse. Booth-Genthe CL, Louie SW, Carlini EJ, Li B, Leake BF, Eisenhandler R, Hochman JH, Mei Q, Kim RB, Rushmore TH, Yamazaki M (2006) J Pharmacol Toxicol Methods 54(1): 78-89
    › Primary publication · 16545584 (PubMed)
  17. Organic anion transporting polypeptide 1B1 activity classified by SLCO1B1 genotype influences atrasentan pharmacokinetics. Katz DA, Carr R, Grimm DR, Xiong H, Holley-Shanks R, Mueller T, Leake B, Wang Q, Han L, Wang PG, Edeki T, Sahelijo L, Doan T, Allen A, Spear BB, Kim RB (2006) Clin Pharmacol Ther 79(3): 186-96
    › Primary publication · 16513443 (PubMed)
  18. Hepatic uptake of the novel antifungal agent caspofungin. Sandhu P, Lee W, Xu X, Leake BF, Yamazaki M, Stone JA, Lin JH, Pearson PG, Kim RB (2005) Drug Metab Dispos 33(5): 676-82
    › Primary publication · 15716364 (PubMed)
  19. Polymorphisms in human organic anion-transporting polypeptide 1A2 (OATP1A2): implications for altered drug disposition and central nervous system drug entry. Lee W, Glaeser H, Smith LH, Roberts RL, Moeckel GW, Gervasini G, Leake BF, Kim RB (2005) J Biol Chem 280(10): 9610-7
    › Primary publication · 15632119 (PubMed)
  20. Identification of amino acids in rat pregnane X receptor that determine species-specific activation. Tirona RG, Leake BF, Podust LM, Kim RB (2004) Mol Pharmacol 65(1): 36-44
    › Primary publication · 14722235 (PubMed)
  21. Ethnicity-dependent polymorphism in Na+-taurocholate cotransporting polypeptide (SLC10A1) reveals a domain critical for bile acid substrate recognition. Ho RH, Leake BF, Roberts RL, Lee W, Kim RB (2004) J Biol Chem 279(8): 7213-22
    › Primary publication · 14660639 (PubMed)
  22. The orphan nuclear receptor HNF4alpha determines PXR- and CAR-mediated xenobiotic induction of CYP3A4. Tirona RG, Lee W, Leake BF, Lan LB, Cline CB, Lamba V, Parviz F, Duncan SA, Inoue Y, Gonzalez FJ, Schuetz EG, Kim RB (2003) Nat Med 9(2): 220-4
    › Primary publication · 12514743 (PubMed)
  23. Human organic anion transporting polypeptide-C (SLC21A6) is a major determinant of rifampin-mediated pregnane X receptor activation. Tirona RG, Leake BF, Wolkoff AW, Kim RB (2003) J Pharmacol Exp Ther 304(1): 223-8
    › Primary publication · 12490595 (PubMed)
  24. Application of three-dimensional quantitative structure-activity relationships of P-glycoprotein inhibitors and substrates. Ekins S, Kim RB, Leake BF, Dantzig AH, Schuetz EG, Lan LB, Yasuda K, Shepard RL, Winter MA, Schuetz JD, Wikel JH, Wrighton SA (2002) Mol Pharmacol 61(5): 974-81
    › Primary publication · 11961114 (PubMed)
  25. Three-dimensional quantitative structure-activity relationships of inhibitors of P-glycoprotein. Ekins S, Kim RB, Leake BF, Dantzig AH, Schuetz EG, Lan LB, Yasuda K, Shepard RL, Winter MA, Schuetz JD, Wikel JH, Wrighton SA (2002) Mol Pharmacol 61(5): 964-73
    › Primary publication · 11961113 (PubMed)
  26. Fruit juices inhibit organic anion transporting polypeptide-mediated drug uptake to decrease the oral availability of fexofenadine. Dresser GK, Bailey DG, Leake BF, Schwarz UI, Dawson PA, Freeman DJ, Kim RB (2002) Clin Pharmacol Ther 71(1): 11-20
    › Primary publication · 11823753 (PubMed)
  27. Identification of functionally variant MDR1 alleles among European Americans and African Americans. Kim RB, Leake BF, Choo EF, Dresser GK, Kubba SV, Schwarz UI, Taylor A, Xie HG, McKinsey J, Zhou S, Lan LB, Schuetz JD, Schuetz EG, Wilkinson GR (2001) Clin Pharmacol Ther 70(2): 189-99
    › Primary publication · 11503014 (PubMed)
  28. Polymorphisms in OATP-C: identification of multiple allelic variants associated with altered transport activity among European- and African-Americans. Tirona RG, Leake BF, Merino G, Kim RB (2001) J Biol Chem 276(38): 35669-75
    › Primary publication · 11477075 (PubMed)
  29. Pharmacological inhibition of P-glycoprotein transport enhances the distribution of HIV-1 protease inhibitors into brain and testes. Choo EF, Leake B, Wandel C, Imamura H, Wood AJ, Wilkinson GR, Kim RB (2000) Drug Metab Dispos 28(6): 655-60
    › Primary publication · 10820137 (PubMed)
  30. Modulation by drugs of human hepatic sodium-dependent bile acid transporter (sodium taurocholate cotransporting polypeptide) activity. Kim RB, Leake B, Cvetkovic M, Roden MM, Nadeau J, Walubo A, Wilkinson GR (1999) J Pharmacol Exp Ther 291(3): 1204-9
    › Primary publication · 10565843 (PubMed)
  31. OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine. Cvetkovic M, Leake B, Fromm MF, Wilkinson GR, Kim RB (1999) Drug Metab Dispos 27(8): 866-71
    › Primary publication · 10421612 (PubMed)
  32. Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein. Kim RB, Wandel C, Leake B, Cvetkovic M, Fromm MF, Dempsey PJ, Roden MM, Belas F, Chaudhary AK, Roden DM, Wood AJ, Wilkinson GR (1999) Pharm Res 16(3): 408-14
    › Primary publication · 10213372 (PubMed)
  33. Human MRP3 transporter: identification of the 5'-flanking region, genomic organization and alternative splice variants. Fromm MF, Leake B, Roden DM, Wilkinson GR, Kim RB (1999) Biochim Biophys Acta 1415(2): 369-74
    › Primary publication · 9889399 (PubMed)
  34. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. Kim RB, Fromm MF, Wandel C, Leake B, Wood AJ, Roden DM, Wilkinson GR (1998) J Clin Invest 101(2): 289-94
    › Primary publication · 9435299 (PubMed) · PMC508566 (PubMed Central)